The KD Pharma Group (Switzerland) has announced that it has successfully completed the acquisition of dsm-firmenich’s (Heerlen, Netherlands) Marine Lipids business. The transaction was announced in July and has now successfully been closed after receiving all customer regulatory approvals.
The acquisition includes dsm-firmenich’s Marine Lipids omega-3 fish oil business for the food and beverage, dietary supplement and pharmaceutical markets, as well as the MEG-3 brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in the enlarged KD group.
“This is a historic day for our company. We are excited about the new opportunities that lie ahead of us, which will allow us to better advance our mission of creating innovative health solutions that help people live better lives,” said Oscar Groet, CEO of KD Pharma Group. “We now have a leadership position throughout the value chain from refined oils to pharmaceutical APIs to soft gel capsule manufacturing. We are committed to ensuring that our customers from both businesses have a seamless experience as we integrate the acquisition and promise they will receive the highest levels of service and market-leading quality.”
For more information, visit www.kdpharmagroup.com or www.dsm-firmenich.com.
